Dr. Abraham Kalikstein, MD

Dr. Kalikstein practices at New York Neurologic Associates in New Hyde Park, New York.

Dr. Kalikstein's NPI, 1245617927, was assigned on May 1, 2015. Dr. Kalikstein holds New York license 296884.

Dr. Kalikstein's primary practice is New York Neurologic Associates, at 3003 New Hyde Park Rd, New Hyde Park, NY 11042 in Nassau County. The practice phone is (516) 488-1888.

Dr. Kalikstein's primary practice is New York Neurologic Associates in New Hyde Park, New York. Dr. Kalikstein is also affiliated with Long Island Jewish Medical Center. The medical group on file is New York Neurologic Associates. Dmand AI also links Dr. Kalikstein to 1 more hospital, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalikstein practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kalikstein's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kalikstein is licensed in New York.

CMS data shows 3,003 Medicare services from Dr. Kalikstein across 28 procedure codes in 2024, for 588 Medicare patients. Medicare paid $221,867 for them.

CMS counts 588 Medicare patients who saw Dr. Kalikstein in 2024. The largest group is 75 to 84, with 228 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalikstein's median patient age at 62, with 59% women.

In 2024, Dr. Kalikstein wrote 1,255 Medicare Part D claims for 284 patients. 88% of them were for generic drugs. CMS names the drug for 1,023 of them, across 31 drugs with 11 or more claims each, at $730,503 in total drug cost. In 2023, CMS named 794 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 68 out of 100 for Dr. Kalikstein for performance year 2024, reported as part of a group. Dr. Kalikstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalikstein as offering telehealth.

Dmand AI links 2 papers to Dr. Kalikstein, published from 2012 to 2013. Dr. Kalikstein's most frequent co-authors are Yoshiya Yamada, MD and Zachary Stephan Zumsteg, MD.

CMS Open Payments shows 1,087 general payments to Dr. Kalikstein from 50 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $4,740.